儿科指南

订阅

MedSci主页 / 所有栏目 / 儿科指南

2021 ELSO指南：新生儿和儿童体外膜氧合治疗后随访

2021-07-22 体外生命支持组织 ASAIO J

体外膜氧合

本文主要针对新生儿和儿童体外膜氧合治疗后的随访提供指导建议。

中文标题：

2021 ELSO指南：新生儿和儿童体外膜氧合治疗后随访

英文标题：

Extracorporeal Life Support Organization (ELSO) Guidelines for Follow-up After Neonatal and Pediatric Extracorporeal Membrane Oxygenation

发布机构：

体外生命支持组织

发布日期：

2021-07-22

简要介绍：

2021年7月，体外生命支持组织(ELSO)发布了新生儿和儿童体外膜氧合治疗后随访指南。接受体外膜氧合（ECMO）治疗的严重或危重症新生儿或儿童有神经损伤、神经发育延迟等风险，本文主要针对新生儿和儿童体外膜氧合治疗后的随访提供指导建议。

相关资料下载：
[AttachmentFileName(sort=1, fileName=Extracorporeal_Life_Support_Organization__ELSO_.1.pdf)] GetToolGuiderByIdResponse(projectId=1, id=6f94b1c002208ac9, title=2021 ELSO指南：新生儿和儿童体外膜氧合治疗后随访, enTitle=Extracorporeal Life Support Organization (ELSO) Guidelines for Follow-up After Neonatal and Pediatric Extracorporeal Membrane Oxygenation, guiderFrom=ASAIO J, authorId=0, author=, summary=本文主要针对新生儿和儿童体外膜氧合治疗后的随访提供指导建议。, cover=https://img.medsci.cn/20211015/1634311204982_5579292.jpg, journalId=0, articlesId=null, associationId=1101, associationName=体外生命支持组织, associationIntro=null, copyright=0, guiderPublishedTime=Thu Jul 22 00:00:00 CST 2021, originalUrl=, linkOutUrl=, content=<p><span style="color: #373737;">2021年7月，体外生命支持组织(ELSO)发布了新生儿和儿童体外膜氧合治疗后随访指南。接受体外膜氧合（ECMO）治疗的严重或危重症新生儿或儿童有神经损伤、神经发育延迟等风险，本文主要针对新生儿和儿童体外膜氧合治疗后的随访提供指导建议。</span></p>, tagList=[TagDto(tagId=50233, tagName=体外膜氧合)], categoryList=[CategoryDto(categoryId=18, categoryName=儿科, tenant=100), CategoryDto(categoryId=38, categoryName=急重症科, tenant=100), CategoryDto(categoryId=85, categoryName=指南&解读, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=0, articleKeyword=, articleKeywordNum=6, guiderKeywordId=50233, guiderKeyword=体外膜氧合, guiderKeywordNum=6, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=指南, guiderLanguage=1, guiderRegion=3, opened=0, paymentType=, paymentAmount=10, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=5976, appHits=59, showAppHits=0, pcHits=1864, showPcHits=5915, likes=1, shares=9, comments=3, approvalStatus=1, publishedTime=Fri Oct 15 23:31:43 CST 2021, publishedTimeString=2021-07-22, pcVisible=1, appVisible=1, editorId=5579292, editor=FUNNYMAN, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=3, createdBy=null, createdName=FUNNYMAN, createdTime=Fri Oct 15 23:24:42 CST 2021, updatedBy=5579292, updatedName=FUNNYMAN, updatedTime=Mon Jan 01 06:58:29 CST 2024, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=, attachmentFileNameList=[AttachmentFileName(sort=1, fileName=Extracorporeal_Life_Support_Organization__ELSO_.1.pdf)])
Extracorporeal_Life_Support_Organization__ELSO_.1.pdf
下载请点击：
评论区 (3)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1062065, encodeId=83bb1062065e7, content=受益, beContent=null, objectType=guider, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=95215641275, createdName=ms7000001149271731, createdTime=Tue Oct 19 21:23:34 CST 2021, time=2021-10-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1060909, encodeId=6c6c106090929, content=好好好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=555f5538552, createdName=微探, createdTime=Sat Oct 16 07:07:45 CST 2021, time=2021-10-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1060906, encodeId=8ff5106090639, content=学习学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=555f5538552, createdName=微探, createdTime=Sat Oct 16 07:07:19 CST 2021, time=2021-10-16, status=1, ipAttribution=)]
    2021-10-19 ms7000001149271731

    受益

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1062065, encodeId=83bb1062065e7, content=受益, beContent=null, objectType=guider, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=95215641275, createdName=ms7000001149271731, createdTime=Tue Oct 19 21:23:34 CST 2021, time=2021-10-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1060909, encodeId=6c6c106090929, content=好好好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=555f5538552, createdName=微探, createdTime=Sat Oct 16 07:07:45 CST 2021, time=2021-10-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1060906, encodeId=8ff5106090639, content=学习学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=555f5538552, createdName=微探, createdTime=Sat Oct 16 07:07:19 CST 2021, time=2021-10-16, status=1, ipAttribution=)]
    2021-10-16 微探

    好好好

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1062065, encodeId=83bb1062065e7, content=受益, beContent=null, objectType=guider, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=95215641275, createdName=ms7000001149271731, createdTime=Tue Oct 19 21:23:34 CST 2021, time=2021-10-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1060909, encodeId=6c6c106090929, content=好好好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=555f5538552, createdName=微探, createdTime=Sat Oct 16 07:07:45 CST 2021, time=2021-10-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1060906, encodeId=8ff5106090639, content=学习学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=555f5538552, createdName=微探, createdTime=Sat Oct 16 07:07:19 CST 2021, time=2021-10-16, status=1, ipAttribution=)]
    2021-10-16 微探

    学习学习

    0

相关指南

ELSO指南：新生儿和儿童体外膜氧合后随访

体外生命支持组织(ELSO,Extracorporeal Life Support Organization) · 2021-07-22

体外膜氧合支持儿科暴发性心肌炎专家共识

中国医师协会体外生命支持专业委员会 · 2020-01-30

成人体外膜氧合循环辅助专家共识

中国医师协会体外生命支持专业委员会 · 2018-03-27

拓展阅读

成人体外膜氧合循环辅助专家共识

中国医师协会体外生命支持专业委员会 · 2018-03-27

体外膜氧合支持儿科暴发性心肌炎专家共识

中国医师协会体外生命支持专业委员会 · 2020-01-30

ELSO指南：新生儿和儿童体外膜氧合后随访

体外生命支持组织(ELSO,Extracorporeal Life Support Organization) · 2021-07-22

2022 ELSO指南：成人和儿童体外膜氧合回路

体外生命支持组织(ELSO,Extracorporeal Life Support Organization) · 2022-01-29

2021年体外生命支持组织《新生儿和儿童体外膜氧合治疗后随访指南》解读

暂未更新 · 2023-09-06

国际专家声明：接受造血细胞移植的成人体外膜氧合

暂未更新 · 2023-03-13